Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Ovarian Cancer (Dec 2019)

Posted by Matt Breese on Dec 27, 2019

Find me on:

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ovarian cancer treatments shows that under the medical benefit, almost 46% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Ovarian Cancer_4Q2019Data snapshot as of Q4 2019

Trends: Most products are limited by their policies for treatment at specific stages of ovarian cancer. This may not remain true as we see clinical trials proving that targeted therapies can provide improvement earlier in the disease cycle and during the maintenance phase.  

To read the full Reality Check on Ovarian Cancer treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing